^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | AZD8186 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting PI3Kß alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Published date:
03/28/2020
Excerpt:
In vitro cell viability assay and immunoblotting demonstrated that PTEN loss was significantly correlated with AZD8186 sensitivity in triple negative breast cancer (TNBC) cell lines.
DOI:
10.18632/oncotarget.27503
Source:
Title:
Targeting PI3Kß alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Published date:
03/28/2020
Excerpt:
AZD8186 in combination with paclitaxel, eribulin had synergistic effects on growth inhibition in PTEN loss cells.
Secondary therapy:
paclitaxel + eribulin mesylate
DOI:
10.18632/oncotarget.27503
